A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
Clinical trial NCT02999672 · COMPLETED
Trial details
- NCT number
- NCT02999672
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-23
- Primary completion
- 2018-04-10
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.